Form 4: Twist Bioscience CEO Sells Shares for Tax Obligations
Insider Transaction Report
Twist Bioscience CEO Emily M. Leproust sold 31,348 shares of common stock at $32.187 per share to cover tax withholding obligations related to PSU vesting.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp. (TWST), reported a sale of common stock.
- The transaction involved the disposition of 31,348 shares at a price of $32.187 per share.
- The sale occurred on October 6, 2025.
- The purpose of the sale was to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs), as mandated by the issuer's equity incentive plans.
- This was a 'sell to cover' transaction and not a discretionary trade by Ms. Leproust.
- Following this transaction, Ms. Leproust directly beneficially owns 601,212 shares of common stock.
- Ms. Leproust also holds 64,950 performance stock options with an exercise price of $67.85, which vested on December 19, 2022, and are exercisable until August 31, 2030.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the reported transaction is a non-discretionary 'sell to cover' sale for tax purposes, rather than a discretionary sale indicating a change in management's confidence.
Positives
- The underlying event for the sale, the vesting of Performance Stock Units (PSUs), indicates that performance criteria were met, which is a positive for the executive.
Negatives
- The sale of shares by an insider, even if non-discretionary, reduces direct insider ownership, which some investors may view with caution.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This insider transaction report is specific to an executive's equity compensation and tax obligations and does not provide information directly related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The transaction represents a minor reduction in direct insider ownership, but its non-discretionary nature mitigates potential negative sentiment.
- Employees: The vesting of Performance Stock Units (PSUs) for the CEO indicates the company's equity compensation plans are functioning as intended.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | Vesting start for an employee stock option with a $5.95 exercise price. |
| 09/28/2017 | Vesting start for an employee stock option with an $8.82 exercise price. |
| 10/31/2019 | Vesting start for an employee stock option with a $26.66 exercise price. |
| 09/01/2020 | Grant date for performance stock options. |
| 10/24/2020 | Vesting start for an employee stock option with a $23.33 exercise price. |
| 12/19/2022 | Performance stock options vested and became exercisable. |
| 09/28/2025 | Expiration date for an employee stock option with a $5.95 exercise price. |
| 10/06/2025 | Transaction date for the common stock sale. |
| 10/08/2025 | Signature date of the Form 4 filing. |
| 09/28/2027 | Expiration date for an employee stock option with an $8.82 exercise price. |
| 11/18/2028 | Expiration date for an employee stock option with a $26.66 exercise price. |
| 10/23/2029 | Expiration date for an employee stock option with a $23.33 exercise price. |
| 08/31/2030 | Expiration date for performance stock options with a $67.85 exercise price. |
Recommendation
holdThe filing reports a mandatory 'sell to cover' transaction by the CEO to satisfy tax obligations upon PSU vesting, not a discretionary sale. This type of transaction is routine and does not reflect a change in management's outlook or confidence in the company, thus not warranting a change in investment recommendation based solely on this filing.
Keywords
Twist Bioscience, TWST, Emily M. Leproust, Insider Transaction, Form 4, Stock Sale, CEO, Tax Withholding, Performance Stock Units, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.